Fundraising Fox
🦊/Companies
Sign in

Complement Therapeutics

Munich, DE · 10 known investors

Find your way into Complement Therapeutics

457 people in our graph share verified history with the Complement Therapeutics team — schools, employers, funds. One of them is your warm intro.

Crystal Huangunlockedknows Muhammad Ali Memon · together at Harvard University (overlapped)
knows the team · via Imperial College London
×9knows the team · via Harvard University
knows the team · via Harvard University/Massachusetts Eye and Ear Infirmary

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration. A University of Manchester spinout, it runs clinical and natural history studies in ophthalmology across the US and UK.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

RHRafiq Hasan
Rafiq HasaninCEO and Managing DirectorSenior Advisor at BioGeneration Ventures
MAMuhammad Ali Memon
Muhammad Ali MemoninChief Medical OfficerMuhammad Ali Memon is a UK-trained ophthalmologist with clinical and research expertise in retinal diseases, previously serving as a consultant at King's College London and honorary consultant at Moorfields Eye Hospital. His background includes experience with clinical trials across multiple phases and research positions at Harvard University and Imperial College London.

Investors · 10

Cambridge Innovation CapitalCambridge · $127K – $12.7M
Hadean VenturesOslo
Seroba Life SciencesDublin · $540K – $7.6M
BGVreported · 2 sourcesSilicon Valley
BioGeneration Venturesreported · 2 sourcesNaarden
Forbionreported · 2 sourcesNaarden
Gimvreported · 2 sourcesAntwerp · $21M – $430M
Panakes PartnersreportedMilan

Also in the syndicate · 2

BioGeneration Ventures (BGV)Panakès Partners

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 3

by search overlap
Inmune Bio7 shared keywordsINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Cellular Origins7 shared keywordsCellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.
Resolution Therapeutics6 shared keywordsResolution develops a macrophage cell therapy to treat end-stage liver disease, aiming to reduce the need for liver transplantation and improve patient outcomes. The company focuses on regenerative medicine for inflammatory and fibrotic diseases.

Companies competing with Complement Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Beacon raises $170M to take on J&J in ocular gene therapy | PackGene Biotechpackgene.com · Jul 2024Complement Therapeutics raises €72M for eye condition gene therapylabiotech.eu · Apr 2023Complement Therapeutics Secures €72 Million in Series A Financing - Hadean Ventureshadeanventures.com · Apr 2023Complement Theraputics Raises Finance - Innovation Factoryuominnovationfactory.com · Feb 2022Complement Therapeutics Ltd raises EUR 5 Million Seed Financing by BGV and Forbion and appoints Dr Rafiq Hasan as CEOprnewswire.com · Feb 2022

Frequently asked questions

What does Complement Therapeutics do?
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration. A University of Manchester spinout, it runs clinical and natural history studies in ophthalmology across the US and UK.
Who are Complement Therapeutics's investors?
Complement Therapeutics's investors include Cambridge Innovation Capital, Hadean Ventures, Seroba Life Sciences, BGV, BioGeneration Ventures, Forbion, Gimv, Panakes Partners.
Where is Complement Therapeutics headquartered?
Complement Therapeutics is headquartered in Munich, DE.